Page 18 - Patrick Wingrove News Today

Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January.

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVies blockbuster arthritis drug Humira, while another drugmaker entered...

(Reuters) - Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, addin...

By Patrick Wingrove (Reuters) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version ...

At least four drugmakers are expected to launch new copycat versions of AbbVie's top-selling rheumatoid arthritis drug, Humira, over the next week, but experts expect little change in prices for the treatment even with the new competition. Drugmakers Boehringer Ingelheim, Sandoz and Organon are expected to launch their biosimilars on Saturday, adding to U.S. competition for the drug that started when Amgen released its copy in January. Usually prices fall, often dramatically, when multipl...

While many large employers have been covering weight-loss drugs, Wegovy's high price and the huge increase in people taking it has them reconsidering that.

Shawnte struggled with her weight for years before she was prescribed Novo Nordisk’s diabetes drug Ozempic for weight loss in 2020, helping the former music industry professional from New York lose more than 50 pounds over two years. But last year, the 46-year-old, who asked to be identified only by her first name to protect her privacy, was told her health insurance would not cover her weight loss treatment. The health insurance plan, which Shawnte's husband received through his j...

By Patrick Wingrove (Reuters) - Shawnte struggled with her weight for years before she was prescribed Novo Nordisk's diabetes drug Ozempic for weight ...

Three organizations on Wednesday said they were suing the US government to block enforcement of a program that gives Medicare the power to negotiate drug prices.

NEW YORK, June 21 (Reuters) - The Pharmaceutical Research and Manufacturers of America (PhRMA), the leading industry lobby group, and two other organizations on Wednesday said they were suing the U.S. governmen...